Mali Zeevi - 18 Mar 2026 Form 3 Insider Report for BioLineRx Ltd. (BLRX)

Role: Chief Financial Officer
Signature: /s/ Mali Zeevi
Issuer symbol: BLRX
Transactions as of: 18 Mar 2026
Net transactions value: $0
Form type: 3
Filing time: 18 Mar 2026, 17:26:21 UTC
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Zeevi Mali	Chief Financial Officer	BIOLINERX LTD., 2 HAMA'AYAN STREET, MODII'N, ISRAEL	/s/ Mali Zeevi	18 Mar 2026	0001993064

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	BLRX	Ordinary Shares, 0.1 NIS per share						1,311,000	18 Mar 2026	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	BLRX	Employee Stock Option (Right to Buy)							18 Mar 2026	Ordinary Shares	43,800	$0.2640	Direct	F1, F2, F10
holding	BLRX	Employee Stock Option (Right to Buy)							18 Mar 2026	Ordinary Shares	126,600	$0.2700	Direct	F1, F3, F10
holding	BLRX	Employee Stock Option (Right to Buy)							18 Mar 2026	Ordinary Shares	280,200	$0.2870	Direct	F1, F4, F10
holding	BLRX	Employee Stock Option (Right to Buy)							18 Mar 2026	Ordinary Shares	454,800	$0.2760	Direct	F1, F5, F10
holding	BLRX	Employee Stock Option (Right to Buy)							18 Mar 2026	Ordinary Shares	704,400	$0.1500	Direct	F1, F6, F10
holding	BLRX	Employee Stock Option (Right to Buy)							18 Mar 2026	Ordinary Shares	1,006,800	$0.1010	Direct	F1, F7, F10
holding	BLRX	Employee Stock Option (Right to Buy)							18 Mar 2026	Ordinary Shares	1,078,800	$0.0450	Direct	F1, F8, F10
holding	BLRX	Employee Stock Option (Right to Buy)							18 Mar 2026	Ordinary Shares	13,680,000	$0.006000	Direct	F1, F9, F10

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Options granted under the 2003 Amended and Restated Share Incentive Plan.
F2	The grant date of this grant is October 9, 2016. This option grant is fully vested as of this date.
F3	The grant date of this grant is February 21, 2017. This option grant is fully vested as of this date.
F4	The grant date of this grant is December 26, 2017. This option grant is fully vested as of this date.
F5	The grant date of this grant is March 25, 2019. This option grant is fully vested as of this date.
F6	The grant date of this grant is November 17, 2020. This option grant is fully vested as of this date.
F7	The grant date of this grant is March 15, 2022. This option grant is fully vested as of this date.
F8	The grant date of this grant is March 21, 2023. As of this date, 741,600 of the options were vested as of the date of appointment. The remaining 337,200 options will vest in 5 equal quarterly installments, subt to the Reporting Person's continued service to the Issuer as of each vesting date.
F9	The grant date of this grant is November 19, 2025. As of this date, none of the options were vested. As of the grant date 3,420,000 options have a one-year cliff and the remaining 10,260,000 options will vest in 12 equal quarterly installments, subject to the Reporting Person's continued service to the Issuer as of each vesting date.
F10	To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2003 Amended and Restated Share Incentive Plan must be registered in the name of a trustee.